Hyaluronan (HA) has an extraordinarily high turnover in physiological tissues, and HA degradation is accelerated in inflammatory and neoplastic diseases. CD44 (a cell surface receptor) and two hyaluronidases (HYAL1 and HYAL2) are thought to be responsible for HA binding and degradation; however, the role of these molecules in HA catabolism remains controversial. Here we show that KIAA1199, a deafness gene of unknown function, plays a central role in HA binding and depolymerization that is independent of CD44 and HYAL enzymes. The specific binding of KIAA1199 to HA was demonstrated in glycosaminoglycan-binding assays. We found that knockdown of KIAA1199 abolished HA degradation by human skin fibroblasts and that transfection of KIAA1199 cDNA into cells conferred the ability to catabolize HA in an endo-β-N-acetylglucosaminidase-dependent manner via the clathrin-coated pit pathway. Enhanced degradation of HA in synovial fibroblasts from patients with osteoarthritis or rheumatoid arthritis was correlated with increased levels of KIAA1199 expression and was abrogated by knockdown of KIAA1199. The level of KIAA1199 expression in uninflamed synovium was less than in osteoarthritic or rheumatoid synovium. These data suggest that KIAA1199 is a unique hyaladherin with a key role in HA catabolism in the dermis of the skin and arthritic synovium. extracellular matrix | hyaluronic acid | hyaluronate | hearing loss H yaluronan (HA) is a high molecular weight, linear glycosaminoglycan (GAG) composed of only two sugars: β-(1,3)-linked-D-glucuronic acid and β-(1,4)-linked-N-acetyl-D-glucosamine. HA is ubiquitously present as a major constituent of the extracellular matrix (ECM) in vertebrate tissues, providing structural and functional integrity to cells and organs. Although many organs maintain high concentrations of HA, skin contains approximately half the total body HA (1). HA is rapidly depolymerized within tissues, from extralarge native molecules of 1,000-10,000 kDa, to intermediate-size fragments of 10-100 kDa present in the extracellular milieu (2). Approximately one-third of total body HA is replaced daily, and the skin is a major determinant organ for HA turnover, with a metabolic half-life of 1-1.5 d (2). HA degradation is enhanced under certain pathological conditions and its lower molecular weight products are commonly detected in diseases, such as arthritis and cancers (3-5). The reduced average molecular weight of HA (as low as 200 kDa) in synovial fluids from patients with osteoarthritis (OA) or rheumatoid arthritis (RA) leads to decreased synovial viscosity and is associated with synovial inflammation (6). In addition, much lower molecular weight HA fragments (∼20 kDa) are known to stimulate neovascularization and facilitate tumor cell motility and invasion (5, 7, 8) .
Hyaluronan (HA) has an extraordinarily high turnover in physiological tissues, and HA degradation is accelerated in inflammatory and neoplastic diseases. CD44 (a cell surface receptor) and two hyaluronidases (HYAL1 and HYAL2) are thought to be responsible for HA binding and degradation; however, the role of these molecules in HA catabolism remains controversial. Here we show that KIAA1199, a deafness gene of unknown function, plays a central role in HA binding and depolymerization that is independent of CD44 and HYAL enzymes. The specific binding of KIAA1199 to HA was demonstrated in glycosaminoglycan-binding assays. We found that knockdown of KIAA1199 abolished HA degradation by human skin fibroblasts and that transfection of KIAA1199 cDNA into cells conferred the ability to catabolize HA in an endo-β-N-acetylglucosaminidase-dependent manner via the clathrin-coated pit pathway. Enhanced degradation of HA in synovial fibroblasts from patients with osteoarthritis or rheumatoid arthritis was correlated with increased levels of KIAA1199 expression and was abrogated by knockdown of KIAA1199. The level of KIAA1199 expression in uninflamed synovium was less than in osteoarthritic or rheumatoid synovium. These data suggest that KIAA1199 is a unique hyaladherin with a key role in HA catabolism in the dermis of the skin and arthritic synovium. HA is ubiquitously present as a major constituent of the extracellular matrix (ECM) in vertebrate tissues, providing structural and functional integrity to cells and organs. Although many organs maintain high concentrations of HA, skin contains approximately half the total body HA (1) . HA is rapidly depolymerized within tissues, from extralarge native molecules of 1,000-10,000 kDa, to intermediate-size fragments of 10-100 kDa present in the extracellular milieu (2) . Approximately one-third of total body HA is replaced daily, and the skin is a major determinant organ for HA turnover, with a metabolic half-life of 1-1.5 d (2) . HA degradation is enhanced under certain pathological conditions and its lower molecular weight products are commonly detected in diseases, such as arthritis and cancers (3) (4) (5) . The reduced average molecular weight of HA (as low as 200 kDa) in synovial fluids from patients with osteoarthritis (OA) or rheumatoid arthritis (RA) leads to decreased synovial viscosity and is associated with synovial inflammation (6) . In addition, much lower molecular weight HA fragments (∼20 kDa) are known to stimulate neovascularization and facilitate tumor cell motility and invasion (5, 7, 8) .
There are six human hyaluronidase-related genes clustered on two chromosomal loci, 3p21.3 (HYAL1, HYAL2, and HYAL3) and 7q31.3 (HYAL4, HYALP1, and SPAM1) (9) . However, because HYALP1 is a pseudogene (9) , and HYAL4 and SPAM1 have restricted expression patterns, HYALP1, HYAL4, and SPAM1 are unlikely to have major roles in constitutive HA degradation in vivo. HYAL3 has a restricted expression pattern (9) and its ability to degrade HA is questionable (10) . Therefore, HYAL1 and HYAL2 are most likely to have key roles in degrading HA.
One current model suggests that high molecular weight HA is tethered to cell surfaces by CD44 (a HA receptor) concentrated in caveolin-rich lipid rafts, and then cleaved by HYAL2 into intermediate-size fragments in acidic microenvironments created by the Na + -H + exchanger (11) . The intermediate-size fragments are degraded to oligosaccharides within cells by lysosomal HYAL1 in coordination with lysosomal β-glucuronidase and β-N-acetyl-glucurosaminidase (12) . However, this model is insufficient to explain the rapid catabolism of HA in vivo. First, neither HYAL1 nor HYAL2 are expressed in the brain (9, 13), a major organ containing large amounts of HA. This finding suggests that other molecules degrade HA in the brain. Second, HYAL2 has little or no hyaluronidase activity (14) , and the finding that HYAL1 degrades HA into oligosaccharides of ∼0.8 kDa intracellularly (10, 12) is inconsistent with the presence of HA catabolites of 10-100 kDa in tissues (2) . Third, mice deficient in the HYAL1 or HYAL2 gene do not show significant accumulation of HA within tissues (15, 16). Finally, the evidence for HA degradation by HYAL1 and HYAL2 was obtained in a breast carcinoma MDA-MB231 cell line (11) and in cells stably transfected with these genes (10); thus, only limited evidence for the direct involvement of HYAL1 and HYAL2 in HA degradation in cells such as fibroblasts is available. Collectively, these lines of evidence reveal that HA degradation by the HYAL enzymes remains elusive, and that new HA-degradation pathways independent of the HYAL1, HYAL2, and CD44 system may exist.
In the present study, we first tested the involvement of HYAL1, HYAL2, and CD44 in HA depolymerization in normal human skin fibroblasts, and found that knockdown of these genes with siRNAs did not abrogate HA depolymerization. This result prompted us to investigate new mechanisms for HA degradation. Using microarray analysis, we screened genes whose expression levels paralleled the extent of HA depolymerization in cultured skin fibroblasts under stimulated conditions. Intriguingly, our data provided unique evidence that a deafness gene of unknown function, known as KIAA1199 (17), has a key role in the binding and depolymerization of HA, and that this activity is independent of CD44 and HYAL enzymes. We also demonstrate that KIAA1199 is expressed predominantly by dermal fibroblasts in normal skin and is overexpressed by synovial fibroblasts and tissues from arthritic joints. (Fig. 1A) . The fibroblasts selectively digested fluoresceinamine-labeled HA of 1,760 kDa (FA-HA H1), but not other FA-labeled GAGs, such as chondroitin sulfate A, C, and D (FA-CSA, FA-CDC, and FA-CSD), dermatan sulfate (FA-DS), heparin (FA-Hep), or heparan sulfate (FA-HS) (Fig. S1) , suggesting that the depolymerizing machinery of the fibroblasts is specific for HA. To study the involvement of CD44 and the enzymes HYAL1 and HYAL2 in HA depolymerization, we examined expression of these molecules and found that skin fibroblasts express CD44 and HYAL2 but not HYAL1 (Fig.  1B) . Interestingly, knockdown of CD44 and HYAL2 using two different siRNAs specific to these molecules showed no effect on HA depolymerization ( Fig. 1 C and D) . These data suggest that the HA-degrading machinery present in Detroit 551 cells is independent of CD44 and HYAL2 or HYAL1.
Results

CD44 and HYAL Enzymes
KIAA1199 Is Required for HA Depolymerization and Expressed by
Dermal Fibroblasts in Normal Skin. To identify molecules involved in the HA depolymerization, we monitored changes in depolymerization in Detroit 551 skin fibroblasts following stimulation with IL-1α, IL-1β, TGF-α, TGF-β1, epidermal growth factor, hepatocyte growth factor, IFN-γ, TNF-α, or histamine, and found that HA depolymerization is strikingly up-regulated and down-regulated only by treatment with histamine and TGF-β1, respectively (Fig. 1E) . Thus, we searched for genes associated with HA depolymerization using microarray analysis and identified 25 genes that were up-regulated by histamine and down-regulated by TGF-β1 (Table S1 ). We then used siRNA to knock down the 25 genes and discovered that transfection of two different siRNAs targeting the KIAA1199 gene abolished HA depolymerization in Detroit 551 cells (Fig. 1F and Fig. S2A ). Similar results were obtained with other human skin fibroblast cell lines, including HS27 (neonatal skin fibroblasts) and NHDF-Ad (adult skin fibroblasts) (Fig. S2 B and C). The HA depolymerizing activity in Detroit 551 cells showed an apparent V max of 370 μg/10 5 cells/72 h and K m of 1,480 μg/mL. Histamine treatment showed a 3.8-fold increase in V max (1,370 μg/10 5 cells/72 h) without affecting K m (1,500 μg/mL) (Fig.  1G ). Under stimulation with histamine, the mRNA and protein expression of KIAA1199 was significantly increased by 3.7-fold (0.37 ± 0.02 vs.1.37 ± 0.04, control vs. histamine; n = 3; P < 0.001) (Fig. 1H ) and 4.2-fold (0.31 ± 0.10 vs. 1.31 ± 0.10; n = 3; P < 0.001) respectively (Fig. 1I) , whereas TGF-β1 reduced the expression to a negligible level ( Fig. 1 H and I) . These results show that KIAA1199 expression is essential for HA depolymerization in skin fibroblasts and the amount of KIAA1199 protein directly determines the velocity of HA depolymerization. In situ hybridization ( Fig. 2A) and immunohistochemistry ( Fig. 2B) showed that KIAA1199 is expressed predominantly by dermal fibroblasts in normal human skin.
Cells Transfected with KIAA1199 cDNA Acquire HA-Degrading Capability.
To further examine the activity of KIAA1199 in HA depolymerization, we transfected HEK293 (human embryonic kidney) and (Fig. S3 ). In addition, KIAA1199/ HEK293 cells degraded FA-HA species with different average molecular weights (FA-M1, 907 kDa; FA-L1, 197 kDa; FA-S1, 56 kDa; FA-T1, 28 kDa; FA-U1, 9.8 kDa) (Fig. S3) . Determination of the terminal sugars on the fragments showed that the reducing and nonreducing terminal sugars were N-acetylglucosamine and glucuronic acid, respectively ( Fig. 3 C and D) , indicating that cleavage occurs at the β-endo-N-acetylglucosamine bonds. Importantly, we found that additional, transient expression of HYAL1 or HYAL2 in KIAA1199/HEK293 cells did not enhance HA degradation (Fig. S4 ).
HA Is Catabolized by KIAA1199 via the Clathrin-Coated Pit Pathway.
Accumulated lines of evidence have shown that HA degradation occurs extracellularly and via receptor-mediated endocytosis (2, (10) (11) (12) (18) (19) (20) . HARE (HA receptor for endocytosis; also called Stabilin-2) and CD44 are thought to be associated with clathrincoated pits and caveolae, respectively (2, 11) . Because KIAA1199 appeared to be located in the cytoplasm and on the cell membrane, as shown in Fig. 2B , we assessed the possible involvement of clathrin-coated pits and caveolae for their roles in HA degradation. When expression of the clathrin heavy chain (CHC) and α-adaptin subunit of AP-2, an adaptor protein complex functioning as a major organizer of clathrin coats, was knocked down by siRNAs in KIAA1199/HEK293 cells, HA degradation was reduced ( Fig. 4 A and B) . In contrast, knockdown of caveolin-1 caused no changes in HA degradation (Fig. 4C) . Immunoprecipitation with anti-KIAA1199 antibody showed that CHC coprecipitates with KIAA1199 (Fig. 4D ). Because these results suggest that the clathrin-coated pit pathway is most likely involved in KIAA1199-mediated HA depolymerization, we further studied the effects of inhibitors on HA degradation. These effects included inhibitors for receptor recycling (monensin), endosomelysosome system acidification (NH 4 Cl), a vacuolar (H + )-ATPase (bafilomycin A1), dynamin, a GTPase implicated in endocytosis and scission of newly formed vesicles (dynasore), and polymerization of microtubules and trafficking from early to late endosome (nocodazole) (19). As shown in Fig. 4E , treatment of KIAA1199/ HEK293 cells with these chemicals, except for nocodazole, inhibited HA depolymerization, suggesting that HA is depolymerized in acidic compartments before endosome-lysosome fusion (e.g., clathrin-coated vesicles or early endosomes). The idea that HA depolymerization is unlikely to occur in lysosomes is supported by the observations that additional expression of lysosomal HYAL1 or HYAL2 in KIAA1199/HEK293 cells did not affect HA depolymerization (Fig. S4) . By immunohistochemistry, KIAA1199 was localized mainly to the vesicles in the periphery of Detroit 551 skin fibroblasts (Fig. S5 A and B) . Double immunostaining of KIAA1199 and CHC in KIAA1199/HEK293 cells showed that signals of both molecules are detected in a vesicular pattern, and KIAA1199 is localized closely to CHC in some vesicles (Fig. S5 C and D) . When localization of high molecular weight HA added to skin fibroblasts and KIAA1199/HEK293 cells was examined by confocal microscopy, HA was observed in the periphery of these cells, showing a vesicular pattern, but no fluorescence was shown by incubation with Streptomyces hyaluronidase-digested HA (Fig. S5 E-G KIAA1199 Has HA-Specific Binding Capability. The interaction between KIAA1199 protein and GAGs was examined by immunoblotting for KIAA1199 in GAG precipitates from the KIAA1199/ HEK293 cell lysates after incubation with GAGs. As shown in Fig.  4F , KIAA1199 was selectively coprecipitated with HA (Fig. 4F , Upper), and also coprecipitated with HA species of varying average molecular weights including HA-H2 (1,452 kDa), HA-M2 (1,039 kDa), HA-L2 (219 kDa), HA-S2 (52 kDa), and HA-T2 (28 kDa) (Fig. 4F, Lower) . In addition, KIAA1199 in KIAA1199/ HEK293 cell lysates could bind to HA-Sepharose beads (Fig. 4G , Upper), and this binding was competitively blocked by preincubation of KIAA1199/HEK293 cell lysates with soluble HA-H2, but not other GAGs (Fig. 4G, Lower) . Note, however that HAdegrading activity was not detected in cell lysates from KIAA1199/ HEK293 cells. Recombinant KIAA1199 protein expressed in a wheat-germ cell-free expression system showed no definitive HA degrading activity at a pH range between 4.0 and 7.0 (Fig. S6 ).
KIAA1199 Is Overexpressed by Synovial Fibroblasts and Synovial Tissues
from OA and RA Patients. To assess the possible role of KIAA1199 in human disease, we next examined HA-degrading activity in cultured synovial fibroblasts. The activity appeared higher in OA and RA synovial fibroblasts compared with normal synovial fibroblasts ( Fig. 5A and Fig. S7 ) and closely correlated with the expression levels of KIAA1199 mRNA and protein (Fig. 5B) . Importantly, knockdown of KIAA1199 by siRNA reduced the HA-degrading activity to almost negligible levels ( Fig. 5A and Fig. S7 ). These data suggest that KIAA1199 is essential for HA degradation in synovial fibroblasts and that overexpression of KIAA1199 elicits enhanced HA degradation in OA and RA synovial cells. Real-time PCR analysis showed that KIAA1199 gene expression tended to be higher in OA synovial tissues (P = 0.088) and was significantly higher in RA synovial tissues (P < 0.05) compared with noninflammatory synovial tissue (Fig. 5C ). In situ hybridization and immunohistochemistry showed that KIAA1199 is expressed mainly by synovial lining and some sublining cells of RA synovial tissues, whereas only background signal was observed with a control sense probe and nonimmune IgG ( 
Discussion
Two hyaluronidases (HYAL1 and HYAL2) and CD44 are thought to have key roles in HA degradation. However, our present experiments on expression of these molecules and KIAA1199, modulation of their expression in normal skin and arthritic synovial fibroblasts, and transfection of KIAA1199 cDNA failed to confirm that notion, and instead provide unique data showing that HA depolymerization mediated by KIAA1199 occurs independently of CD44/HYALs. We found that: (i) normal human skin and arthritic synovial fibroblasts degrade HA into intermediate-sized fragments, dependent on the expression of KIAA1199; (ii) transfection of KIAA1199 cDNA confers the ability to specifically bind to and degrade HA; (iii) overexpression of HYAL1 or HYAL2 in KIAA1199 transfectants does not increase HA depolymerization; and (iv) HA depolymerization by KIAA1199 involves the clathrin-coated pit pathway, rather than the caveolae pathway via CD44 and HYAL2.
Extralarge (1,000-10,000 kDa) native HA molecules within tissues are initially depolymerized into intermediate fragments of 10-100 kDa (2) . Most fragments are then released from the ECM, drained into lymphatic vessels, and catabolized within the lymph nodes (2) . The remaining HA fragments reach the circulation and are fully degraded by an acid-active hyaluronidase in lysosomes following HARE-mediated clathrin-coated pit endocytosis, predominantly in the liver, kidney, and spleen (2), where both HYAL1 and HYAL2 are highly expressed (9, 13) . Patients with mucopolysaccharidosis (MPS) IX caused by HYAL1 deficiency in humans, and HYAL2 knockout mice, show elevated levels of HA in the plasma (13, 16) . Lysosomal accumulation of HA is also known in MPS IX patients within macrophages and fibroblasts (13) and HYAL1 knockout mice within chondrocytes (15). These data suggest that HYAL1 and HYAL2 contribute to HA degradation via HARE-and CD44-mediated endocytosis in these organs. However, these HYAL enzymes are not expressed in the brain (9, 13), indicating a requirement for an alternative pathway in the brain. KIAA1199 is expressed in a wide range of normal human tissues, including brain, lung, pancreas, testis, and ovary, but its expression is notably absent in the liver, kidney, and spleen (21). Therefore, it seems likely that KIAA1199 may have a more ubiquitous role in HA catabolism in tissues that do not express HYAL1 or HYAL2, such as the brain. Moreover, our data show that KIAA1199, but not the HYAL enzymes, is involved in HA degradation in normal skin fibroblasts and arthritic synovial fibroblasts. The differential roles of KIAA1199 and the CD44/HYALs system in degrading HA in other tissues remain to be clarified in future work.
The KIAA1199 protein sequence shows no substantial homology to other molecules, including HYAL enzymes, HA-binding proteins, and bacterial hyaluronidases (9, 12) , and lacks HA-link modules (22), B(X 7 )B HA-binding motifs (23), and the transmembrane domain (21). However, the protein has two GG domains, consisting of two well-conserved Gly residues, one G8 domain that contains eight conserved Gly residues in five β-strand pairs (24, 25), four PbH1 domains (26), and seven predicted N-glycosylation sites (26). In the present study, we have shown that mutations of the ARG 187 residue (R187C and R187H) located in the GG domain eliminate HA-degrading activity. No information is available for the function of the GG domain at present, but the G8 domain has predicted roles in extracellular ligand binding (25). In addition, the cellular role of PbH1 domain is supposed to be polysaccharide hydrolysis according to the InterPro member database SMART (www.ebi.ac.uk/interpro). Thus, it is possible to speculate that the GG and G8 domains and PbH1 domains are responsible for KIAA1199-mediated binding and depolymerization of HA. Like HYAL2 (14) , cell lysates of KIAA1199 stable transfectants or recombinant KIAA1199 protein lacked HA depolymerizing activity. This lack could reflect the need for a specific conformational change in KIAA1199 that is conferred by its microenvironment or interactions with other molecules. Because our study showed that KIAA1199 is located near the CHC + small vesicles, and KIAA1199-mediated HA degradation is dependent on vacuolar (H + )-ATPase and dynamin, the acidic, dynamic and energy-coupling microenvironment may be critical for KIAA1199 activity. Alternatively, we cannot exclude the possibility that KIAA1199 may function as an adaptor molecule for an unknown hyaluronidase. It is well known that free radicals randomly attack HA chains, generating HA fragments of various sizes (27). However, our finding that KIAA1199 can mediate HA cleavage at β-endo-N-acetylglucosamine bonds shows that HA degradation by KIAA1199 is independent of freeradical activity.
The study presented here shows that KIAA1199 gene expression is up-regulated and down-regulated by histamine and TGF-β1, respectively. A reduction in molecular weight and mass of HA because of increased HA degradation is commonly observed in arthritic synovial fluids (3, 4) and in the dermis of the UV-damaged skin (28). Under these pathological conditions, locally, overproduced histamine is released from mast cells into the extracellular environment (29, 30). It is therefore plausible that up-regulation of KIAA1199 expression by histamine enhances HA degradation in these conditions. In contrast, TGF-β1 plays an essential role in the overproduction of ECM molecules, including HA, under pathophysiological conditions such as wound healing (31). Although accumulation of HA within wounded tissues is explained mainly by enhanced HA synthesis following TGF-β-induced expression of HA synthases 1 and 2 (32), our data suggest that TGF-β1 might simultaneously down-regulate HA degrading activity by reducing KIAA1199 gene expression, which contributes further to the accumulation of HA.
We have shown that the R187C and R187H mutants of KIAA1199 substantially reduce HA depolymerization. HA is present in the inner ear as a molecular filter against intercellular ionic leakage (33) and KIAA1199 is highly expressed in the spiral ligament of the cochlea (17), which has an important role in the homeostasis of inner ear fluids (33). Thus, a decline in HA catabolism might affect the static equilibrium of electrolytes and water in the inner ear fluids, causing hearing impairment. Another possible link between KIAA1199 and genetic disorders is Werner syndrome. Werner syndrome is an adult-onset progeroid disease caused by mutations in the WRN gene encoding a protein with helicase and exonuclease activities (34). Interestingly, Werner patients show hyperhyaluronic aciduria together with elevated serum HA concentration (35) and scleroderma-like skin with an aged appearance, characterized by reduced amounts of HA (36). Skin fibroblasts isolated from a patient with Werner syndrome overexpress KIAA1199 (21) and generate small molecular weight HA (37). Although further studies are needed to obtain direct evidence, it is tempting to speculate that enhanced degradation and release of HA from the skin by fibroblasts overexpressing KIAA1199 may contribute to the clinical characteristic of Werners syndrome. Previous studies have shown that KIAA1199 is up-regulated in gastric and colorectal cancers and immortalized renal cell carcinomas, and a splice variant is detected in primary colon adenocarcinomas, although the functional significance of these findings is not clear (21, 26, 38 ). In addition, enhanced expression and activity of HYAL1 and HYAL2/CD44 are reportedly related to growth and malignancy of tumor cells (11, 39) . Because HA fragments of <20 kDa can induce inflammation by promoting angiogenesis (7, 8) and cell migration (5), one can postulate that HA fragments generated by KIAA1199 or HYAL enzymes might contribute to enhanced neovascularization and tumor cell invasion in cancer tissues. However, further detailed studies are necessary to better understand the roles of KIAA1199 and HYAL enzymes in cancer.
In summary, the present study provides evidence that KIAA1199 is a unique HA-binding protein, with a role in HA catabolism, that is independent of CD44 and HYAL enzymes. The expression of (1) with some modifications. Confluent Detroit 551 fibroblasts were incubated with 10 μCi/mL of D- [1, H(N)]glucosamine hydrochloride (American Radiolabeled Chemicals). The conditioned medium was pooled, digested with 0.3 mg/mL pronase (Merck), and precipitated with ethanol. The pellets were resuspended in distilled water, and reprecipitated with 1.5% (wt/vol) cetylpyridinium chloride (CPC) solution containing 0.03 M NaCl. The step was repeated by dissolving in 0.1% CPC solution containing 0.4 M NaCl and precipitating with ethanol. The pellets were suspended in 5 mM phosphate buffer, pH 7.5 and applied to a Sepharose CL-2B column (1 × 60 cm) equilibrated with 0.5 M NaCl in distilled water. The Vo fractions were collected, precipitated with ethanol, and finally dissolved in 5 mM phosphate buffer, pH 7.5. The specific activity of purified [ 3 H]HA of >1,000 kDa was 1.3-2.7 × 10 5 dpm/μg (2.2-4.5 kBq/μg). This material was confirmed to be degraded with Streptomyces hyaluronidase (Seikagaku).
Assay for Cellular [
3 H]HA Depolymerization. Cellular depolymerization of high-molecular-weight HA was assayed by culturing confluent cells in medium containing [ 3 H]HA of >1,000 kDa (40,000 dpm/mL) and by applying the media to a Sepharose CL-2B (GE Healthcare) column (1 × 60 cm) equilibrated with 0.5 M NaCl in distilled water. The flow rate was 0.65 mL/min, and fractions of 2.5 mL were collected. The radioactivity of each fraction was measured by a scintillation counter (Aloka; LSC-6100). The column was calibrated with fluoresceinamine (FA)-HA species: FA-HA H1 (1,760 kDa), M1 (907 kDa), L1 (197 kDa), S1 (56 kDa), T1 (28 kDa), and U1 (9.8 kDa) (peak top kDa), all of which were purchased from PG Research. For detection of FA, an excitation wavelength of 490 nm and an emission wavelength of 525 nm were used.
Screening of Stimulators and Suppressors for [ 3 H]HA-Depolymerizing
Activity and Microarray Gene Analysis. Detroit 551 skin fibroblasts treated with or without 10 μM histamine, 10 ng/mL TGF-β1, 10 ng/mL IL-1α, 10 ng/mL IL-1β, 10 ng/mL TGF-α, 10 ng/mL epidermal growth factor, 10 ng/mL hepatocyte growth factor, 10 ng/mL IFN-γ, or 10 ng/mL TNF-α were incubated with [ ]HA-degrading activity, respectively, genes associated with HA degradation were examined by microarray gene expression analysis. Detroit 551 cells were cultured with or without 10 μM histamine or 10 ng/mL TGF-β1 for 8 and 24 h, and then total RNAs isolated using RNeasy (Qiagen) were subjected to Agilent 44K4 chips (Agilent Technologies). Data were analyzed by calculating fold-expression of genes in histamine-stimulated or TGF-β1-stimulated cells against those in untreated cells.
Apparent K m and V max for Cellular HA Depolymerization. A mixture of [ 3 H]HA and nonlabeled high molecular weight HA (human umbilical cord HA; Seikagaku) was added to Detroit 551 skin fibroblasts at concentrations of 100, 300, 600, and 1,250 μg/mL, and cultured in the presence or absence of 10 μM histamine for 72 h. Then, conditioned media were harvested and applied to a Sepharose CL-2B column. HA depolymerization was estimated by monitoring decreases in the total radioactivity of high molecular weight fractions. Cellular HA depolymerizing activity (μg/10 5 cells/ 72 h) was calculated according to the following formula: HA added to cells (μg) × (total radioactivity of high molecular weight fractions before culture − those after 72-h culture)/total added radioactivity/number of cultured cells (× 10 5 cells).
Antibodies. Rat monoclonal antibody against human KIAA1199 was developed according to the established protocols (2) , which corresponds to the amino acid residues Ala 762 to Glu 777 of KIAA1199 (GenBank accession no. NM_018689) and has no homology to other proteins. Individual antibody-expressing clones were screened by immunoblotting for reactivity with recombinant KIAA1199 protein produced in HEK293 cells and by wheat-germ cell-free expression system (Fig. S6A) . Anti-human hyaluronidase 2 (HYAL2) polyclonal antibodies were raised in a rabbit against a peptide with the amino acid sequence of CF 78 YRDRLGLYPRFDSAGRSV 96 (3) and specific antibodies were affinity-purified using the peptide. Antibodies against CD44, clathrin heavy chain (CHC), caveolin-1, α-adaptin, and GAPDH were purchased from Santa Cruz Biotechnology. Control rat IgG 2a κ was purchased from SouthernBiotech.
Analysis of HA-Specific Depolymerization. Detroit 551 and KIAA1199/ HEK239 cells were cultured in medium containing FA-labeled glycosaminoglycans (GAGs): FA-HAs (H1, M1, L1, S1, T1, and U1); chondroitin sulfate A, C, and D (FA-CSA, FA-CSC, and FA-CSD); dermatan sulfate (FA-DS); heparin (FA-Hep); and heparan sulfate (FA-HS) (10 μg/mL each). All of these FA-GAGs were purchased from PG Research. After a 72-h incubation period, the media were harvested and fractionated on a Sepharose CL-6B (GE Healthcare) column (1 × 35 cm) equilibrated with PBS. Fractions of 1.6 mL were collected at 0.4 mL/min and the amounts of FA-GAGs in each fraction were determined by fluorescence counting.
Immunoprecipitation. KIAA1199/HEK293 cells were lysed in icecold 50 mM Tris • HCl buffer, pH 7.5 containing 1 mM EDTA, 1% Triton X-100, 150 mM NaCl, and a mixture of proteinase inhibitors (Roche Diagnostics) (lysis buffer). Lysates were cleared by centrifugation, and KIAA1199 in the supernatants was immunoprecipitated using Dynal magnetic beads protein G (Invitrogen) covered with monoclonal antibody against KIAA1199. Rat IgG2aκ was used as a negative control. Beads were washed and then incubated with NuPAGE LDS sample-loading buffer (Invitrogen) for 10 min at 70°C. The samples were electrophoresed on NuPAGE 4-12% Bis • Tris gels (Invitrogen) and analyzed by immunoblotting using anti-KIAA1199 antibody and anti-CHC antibody.
Immunoblotting. To examine expression of KIAA1199, CD44, HYAL2, CHC, α-adaptin, caveolin-1, and GAPDH proteins, cell supernatant homogenates were separated by electrophoresis on NuPAGE 4-12% Bis • Tris gels (Invitrogen) and proteins were transferred onto polyvinylidene difluoride membranes. The membranes were reacted with the antibodies specific to KIAA1199, CD44, HYAL2, CHC, α-adaptin, caveolin-1, or GAPDH. The antibodies against KIAA1199 and HYAL2 were prepared in the present study and others were purchased from Santa Cruz Biotechnology. Primary antibodies were detected with horseradish peroxidase-conjugated secondary antibodies as follows: horseradish peroxidase-labeled donkey anti-rat IgG antibody for KIAA1199 (Jackson ImmunoResearch); goat anti-rabbit IgG antibody for HYAL2, CD44, caveolin-1, and GAPDH (DAKO); rabbit antimouse IgG antibody for α-adaptin (DAKO); and rabbit anti-goat IgG antibody for CHC (DAKO). Immunoreactive bands were detected with chemiluminescence detection by SuperSignal West Pico Chemiluminescent Substrate system (Thermo Scientific).
RT-PCR and Real-Time PCR. Total RNA was isolated using RNeasy (Qiagen) and cDNA synthesis was done using a High Capacity cDNA Archive Kit (Applied Biosystems). RT-PCR of HYAL1, HYAL2, CD44, and housekeeping gene GAPDH was done, and specific PCR amplification from the target mRNAs was confirmed by sequencing of PCR products using Applied Biosystems 3730xl DNA Analyzer (Life Technologies). PCR amplification was done after denaturing at 95°C for 5 min on a thermal cycler using GeneAmp PCR system 9700 (Applied Biosystems) by running 30 cycles under the following condition: denaturation for 30 s at 94°C; annealing for 30 s at 55°C; and extension for 60 s at 72°C. Nucleotide sequences of the primers were as follows: sense primer 5′-CAGGCGTGAGCTGGATGGAGA-3′ and antisense primer 5′-GTATGTGCAACACCGTGTGGC-3′ for HYAL1; sense primer 5′-GAGTTCGCAGCACAGCAGTTC-3′ and antisense primer 5′-CACCCCAGAGGATGACACCAG-3′ for HYAL2; sense primer 5′-TCCCAGTATGACACATATTGC-3′ and antisense primer 5′-CACCTTCTTCGACTGTTGAC-3′ for CD44; and sense primer 5′-ACCACAGTCCATGCCATCAC-3′ and antisense primer 5′-TCCACCACCCTGTTGCTGTA-3′ for GAPDH. The expected sizes of the amplified cDNA fragments for HYAL1, HYAL2, CD44, and GAPDH were 400, 446, 549, and 452 bps, respectively. For quantitative analysis of KIAA1199 expression, cDNA was used as template in a TaqMan real-time PCR assay (ABI Prism 7700 Sequence Detection System; Applied Biosystems) according to the manufacturer's protocol. The relative quantification value of KIAA1199 was normalized to endogenous GAPDH. The total gene specificity of nucleotide sequences chosen for the primers and probe and the absence of DNA polymorphisms were ascertained by BLASTN and Entrez on Web sites (www.ncbi.nlm.nih.gov).
of KIAA1199 in HEK293 cells (KIAA1199/HEK293 cells), HEK293 cells were transfected with the pcDNA3.1(-) vectors containing the KIAA1199 cDNA and stable transfectants were selected by culturing in medium containing 800 μg/mL of G418 (Sigma). The expression and activity of KIAA1199 were monitored by immunoblotting and by the HA-degrading assay, respectively. Inhibitory effects on depolymerization of [ ]HA, because these enzymes cleave individual sugar residues from the nonreducing terminus. To determine the reducing terminal sugar of depolymerized HA, KIAA1199/HEK293 cells were cultured for 72 h in the medium containing nonlabeled human umbilical cord HA (100 μg/mL). The medium concentrated with ethanol was applied to a Sepharose CL-2B column. The depolymerized HA in the fractions were collected, precipitated with ethanol, and finally dissolved in distilled water. Pyridylamination of the reducing terminal sugar of depolymerized HA was done using 2-aminopyridine according to previous methods (6) . Pyridylaminated HA (PA-HA) was acid hydrated with 4 N HCl, followed by N-acetylation with 5% (vol/vol) acetic anhydride (7). PA-HA was purified by reverse-phase HPLC using a TSK-gel Sugar AXI (4.6 mm inner diameter × 15 cm; Tosoh) with a 0.7 M potassium borate buffer, pH 9.0 containing 10% (vol/vol) acetonitrile at a flow rate of 0.3 mL/min at 65°C. PA-GLcNA was detected at an excitation wavelength of 310 nm using an emission wavelength of 380 nm.
Immunofluorescence Microscopy for KIAA1199 in Detroit 551 Skin Fibroblasts and KIAA1199/HEK293 Cells. Detroit 551 fibroblasts and KIAA1199/HEK293 cells were grown on glass multichamber slides (BD Biosciences) to 70-80% confluence, washed in PBS, and fixed with 4% (wt/vol) paraformaldehyde in PBS for 10 min. After washing in PBS containing 0.05% Tween 20 (PBS-T), the cells were reacted with rat anti-KIAA1199 monoclonal antibody conjugated to Alexa-Flour 488. The samples were counterstained with TO-PRO-3 (Invitrogen) and mounted in vectashield (Vector). For double-immunostaining of KIAA1199 and CHC in KIAA1199/ HEK293 cells, the cells were fixed with 4% (wt/vol) paraformaldehyde, reacted with rat anti-KIAA1199 antibody conjugated to Alexa-Flour 488 and goat anti-CHC antibody conjugated to Alexa-Flour 555, and then mounted in vectashield without nuclear counterstaining. As for controls, samples were reacted with nonimmune IgG conjugated to Alexa-Flours. Conjugation of Alexa-Flours to antibodies and nonimmune IgG was performed by Alexa-Fluor antibody labeling kit (Invitrogen) according to the manufacturer's protocol. These samples were observed using Zeiss LSM 510 confocal microscope (Carl Zeiss).
Cellular Distribution of Exogenously Added HA in Detroit 551 Skin
Fibroblasts and KIAA1199/HEK293 Cells. The cells grown on glass multichamber slides were incubated in the presence or absence of 0.1 mg/mL biotin-labeled high molecular weight HA of 1,410 kDa (PG Research) at 37°C for 1 h. The cells were washed with PBS and then fixed with 4% (wt/vol) paraformaldehyde in PBS. After washing in PBS-T, incubation with streptavidin conjugated to Alexa-Fluor 488 (Invitrogen), and nuclear counterstaining with TO-PRO-3, they were mounted in vectashield and observed using Zeiss LSM 510 confocal microscope. As for control, the cells were incubated with biotin-labeled high-molecular-weight HA digested with Streptomyces hyaluronidase (Seikagaku), followed by the immunostaining described above.
Determination of Extracellular, Cell Surface-Associated, and Intracellular HA. KIAA1199/HEK293 and control HEK293 cells were cultured in six-well plates in the medium containing [ 3 H]HA (400,000 dpm/mL) for 1, 6, or 24 h, and washed with ice-cold PBS. The medium and wash were combined and designated as "extracellular" fraction. The cells were removed from the well by incubation with 0.25% trypsin (Sigma) containing 1 mM EDTA for 3 min at 37°C and washed with PBS. The resulting cell suspension and wash were combined and centrifuged at 4°C. The resulting supernatant was designated as "cell surface-associated" fraction. The cell pellet was digested with 400 μg/mL proteinase K (Invitrogen) in 50 mM Tris • HCl, pH7.4 at 37°C for 24 h, and digestion product was designated as the "intracellular" fraction. The radioactivity of each fraction was measured by a scintillation counter (Aloka; LSC-6100).
Detection of HA-Degrading Activity of HYAL1 by Zymography.
KIAA1199/HEK293 cells were transfected with expression vectors containing the HYAL1 cDNA or empty vectors (Mock). The cell lysates were electrophoresed on SDS gels containing 100 μg/mL human umbilical cord HA (Seikagaku) under nonreducing conditions (8) . After electrophoresis, the gels were washed with 3% (vol/vol) Triton X-100 in distilled water at 4°C for 1 h to remove SDS and then incubated in 100 mM sodium formate buffer, pH 3.7 containing 1% Triton X-100 and 150 mM NaCl at 37°C overnight. Then, the gels were treated with 0.1 mg/mL pronase (Merck) in 20 mM Tris • HCl, pH 8.0 for 2 h at 37°C. The HA degrading activity of HYAL1 was detected as a transparent band against a blue background in the gels stained with 0.5% Alcian Blue 8GX (Wako).
Coprecipitation of KIAA1199 Protein with GAGs. KIAA1199 protein-GAG complexes were precipitated by CPC according to previous methods (9, 10) with some modifications. KIAA1199/HEK293 cells were washed three times with 50 mM phosphate buffer, pH 6.0 and homogenized in 50 mM phosphate buffer, pH 6.0 containing a mixture of proteinase inhibitors (Roche Diagnostics). Aliquots of the homogenate supernatant (50 μL) were mixed with 50 μL of 1 mg/mL aqueous solutions of nonlabeled GAGs: CSA, CSC, CSD, DS, Hep, HS, HA-H2 (1,452 kDa), HA-M2 (1,039 kDa), HA-L2 (219 kDa), HA-S2 (52 kDa), and HA-T2 (28 kDa) (PG Research), or H 2 O (negative control). After the samples were incubated for 1 h at 37°C, 1% CPC [final concentration; (wt/vol)] was added to the GAG/lysate mixtures and incubated for 1 h. The precipitates were pelleted by centrifugation, washed three times with 1 mL of 1% CPC containing 30 mM NaCl, and then dissolved in 50 μL of NuPAGE LDS sample-loading buffer (Invitrogen). The samples were electrophoresed on NuPAGE 4-12% Bis • Tris gels (Invitrogen) under reducing conditions and immunoblotted with anti-KIAA1199 monoclonal antibody.
Binding of KIAA1199 to HA-Sepharose. HA-Sepharose was prepared by incubation of 120 mg human umbilical cord HA (Seikagaku) in 10 mL of water with 10 mL EAH Sepharose 4B beads (GE Healthcare) according to previous methods (11) . After addition of 0.28 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiiamide hydrochloride (Thermo Scientific), the pH was maintained at 4.5-5.0 for 24 h by addition of 0.1 M HCl. The beads were washed sequentially with 1 M NaCl, 0.1 M Tris • HCl buffer, pH 8.1, 0.05 M formate buffer, pH 3.1, and then equilibrated with 50 mM phosphate buffer, pH 6.0 containing 0.1% (vol/vol) Triton X-100. KIAA1199/ HEK293 cells were washed three times with 50 mM phosphate buffer, pH 6.0 containing 0.1% (vol/vol) Triton X-100 and homogenized in the same buffer containing a mixture of proteinase inhibitors (Roche Diagnostics). Aliquots of the homogenate supernatants were incubated with control unsubstituted or HA-coupled Sepharose beads for 1 h at 37°C. The samples were washed with equilibration buffer and materials bound to the beads were eluted by incubation with NuPAGE LDS sample-loading buffer (Invitrogen). Eluates were then electrophoresed on NuPAGE 4-12% Bis • Tris gels (Invitrogen) and immunoblotted with anti-KIAA1199 monoclonal antibody. The specificity of KIAA1199 binding was examined by competition experiments in which free GAGs including HA-H2, CSA, CSC, CSD, DS, Hep, and HS (0.5 mg/mL each) were incubated with homogenate supernatants for 1 h at 37°C before application to HA-Sepharose beads.
HA-Degrading Activity of Recombinant KIAA1199. Wheat-germ cellfree protein synthesis was done using WEPRO1240H Expression kit (CellFree Sciences) according to the manufacturer's protocol. HAdegrading activity of recombinant KIAA1199 was measured by incubation of the synthesized recombinant protein with [ 3 H]HA (40,000 dpm/mL) in 50 mM acetate buffer, pH 4.0 and pH 5.0 or 50 mM phosphate buffer, pH 6.0 and pH 7.0 at 37°C, followed by Sepharose CL-2B column chromatography and scintillation counting of the fractions.
Human Tissue Samples. Normal human skin tissues were taken with a biopsy punch from the faces of the three volunteers (women; age range of 61-65 y) at Stephens & Associates. Collection of skin tissues was approved by the Institutional Review Board of Stephens & Associates and informed consent was obtained from the volunteers before surgery. Synovial tissues were obtained at the time of arthroplasty from knee joints of the patients with OA (n = 10) or RA (n = 8). Noninflammatory synovial tissues (n = 3) were taken at arthroscopic examination approximately 1 y after reconstruction surgery of the anterior cruciate ligament. OA and RA were diagnosed according to the criteria of the American College of Rheumatology (12, 13) . Informed consent was obtained from the patients for the experimental use of the surgically removed synovial samples according to the ethics guidelines of Keio University Hospital.
Immunohistochemistry. Immunohistochemical studies were done on paraffin sections of formalin-fixed human skin and rheumatoid synovium. After rehydration, antigen retrieval was done with 1 mM EDTA, pH 8.0 for 15 min at 95°C. Endogenous peroxidase activity and nonspecific binding were blocked by incubation with 3% (vol/ vol) H 2 O 2 in PBS for 15 min and 10% (vol/vol) donkey serum in PBS containing 1% BSA and 0.05% Tween 20 (BSA/PBS-T) for 30 min, respectively. The sections were incubated with the monoclonal antibody against KIAA1199 or control rat IgG 2a κ at a concentration of 4 μg/mL in BSA/PBS-T for 18 h at 4°C. After washing in PBS, the sections were incubated with horseradish peroxidase-conjugated donkey anti-rat IgG antibody (dilution of 1:500 in BSA/PBS-T; Jackson ImmunoResearch) for 1 h at room temperature. Color was developed by reacting with the Vector DAB (brown; Vector Laboratories) or Vector VIP kit (purple; Vector Laboratories).
In Situ Hybridization. Digoxigenin-labeled KIAA1199 anti-sense and sense riboprobes were synthesized (GenBank accession no. NM_018689, nucleotides 5729-6352). In situ hybridization was done on paraffin sections of formalin-fixed human normal skin and rheumatoid synovium as described previously (14) . Detroit 551 cells were cultured in the presence and absence of 10 μM histamine or 10 ng/mL TGF-β1. At 8 h and 24 h after the treatment, total RNAs were isolated and subjected to microarray gene-expression analysis. Values (fold-induction) represent the ratio of expression levels in the stimulated cells compared with the untreated control cells. 
